公开(公告)号：US12247070B2

公开(公告)日：2025-03-11

申请号：US17418681

申请日：2019-12-26

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol Kim ,  Dong Sik Kim ,  Jae-Keun Lee ,  Juwon Shim

IPC: C07K16/24 ,  A61P9/10 ,  A61K39/00

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.

公开(公告)号：US20240360209A1

公开(公告)日：2024-10-31

申请号：US18623647

申请日：2024-04-01

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Wonkyum KIM ,  Jeongwon YOON ,  Junho CHUNG ,  Junyeong JIN ,  Eunhwoi YOU

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P35/00

CPC classification number: C07K16/24 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6845 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20240182555A1

公开(公告)日：2024-06-06

申请号：US18360143

申请日：2023-07-27

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24

CPC classification number: C07K16/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.

公开(公告)号：US11746149B2

公开(公告)日：2023-09-05

申请号：US16626630

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol Kim ,  Dong Sik Kim ,  Soon-gu Kwon

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/24

CPC classification number: C07K16/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.

公开(公告)号：US11634484B2

公开(公告)日：2023-04-25

申请号：US17050056

申请日：2019-04-24

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol Kim ,  Dong Sik Kim ,  Soon-Gu Kwon

IPC: C07K16/24 ,  A61P25/02 ,  A61K45/06

Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.

公开(公告)号：US20220242910A1

公开(公告)日：2022-08-04

申请号：US17579463

申请日：2022-01-19

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Jae Young SEONG ,  Jong-Ik HWANG ,  Dong-Hoon KIM ,  Gi Hoon SON ,  Yoo-Na LEE ,  Seongsik YUN ,  Arfaxad REYES-ALCARAZ

IPC: C07K7/08 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61P25/06 ,  A61K9/00 ,  A61K9/19

Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.

公开(公告)号：US20220073601A1

公开(公告)日：2022-03-10

申请号：US17475214

申请日：2021-09-14

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Jae-Keun LEE ,  Dong Sik KIM

IPC: C07K16/24 ,  G01N33/68

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.

公开(公告)号：US20250067755A1

公开(公告)日：2025-02-27

申请号：US18776405

申请日：2024-07-18

Applicant: Neuracle Science Co., Ltd.

Inventor： Jae Young SEONG ,  Byung Joo HAM ,  Min-Hyeok LEE ,  Nui HA

IPC: G01N33/68 ,  C07K16/24 ,  C12Q1/6883

Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.

公开(公告)号：US12077579B2

公开(公告)日：2024-09-03

申请号：US17475214

申请日：2021-09-14

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol Kim ,  Jae-Keun Lee ,  Dong Sik Kim

IPC: G01N33/53 ,  C07K16/24 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/24 ,  G01N33/6863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.

公开(公告)号：US20240166735A1

公开(公告)日：2024-05-23

申请号：US18350287

申请日：2023-07-11

Applicant: Neuracle Science Co., Ltd.

Inventor： Jae Young SEONG ,  Jong Ik HWANG ,  Woong SUN ,  Eun Bee CHO ,  Won-Ki KIM

IPC: C07K16/24 ,  A61K38/17 ,  A61K48/00 ,  C07K14/47 ,  C07K16/18 ,  C12N15/113 ,  C12Q1/6886 ,  G01N33/577 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/24 ,  A61K38/1709 ,  A61K48/00 ,  C07K14/4701 ,  C07K14/4702 ,  C07K16/18 ,  C12N15/113 ,  C12Q1/6886 ,  G01N33/577 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/141 ,  C12Q2600/156 ,  G01N2333/47

Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.